130 related articles for article (PubMed ID: 36765826)
1. Uterine Cavity Lavage Mutation Analysis in Lithuanian Ovarian Cancer Patients.
Žilovič D; Vaicekauskaitė I; Čiurlienė R; Sabaliauskaitė R; Jarmalaitė S
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765826
[TBL] [Abstract][Full Text] [Related]
2. Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study.
Maritschnegg E; Wang Y; Pecha N; Horvat R; Van Nieuwenhuysen E; Vergote I; Heitz F; Sehouli J; Kinde I; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Speiser P; Zeillinger R
J Clin Oncol; 2015 Dec; 33(36):4293-300. PubMed ID: 26552420
[TBL] [Abstract][Full Text] [Related]
3. Uterine lavage identifies cancer mutations and increased
Ghezelayagh TS; Kohrn BF; Fredrickson J; Manhardt E; Radke MR; Katz R; Gray HJ; Urban RR; Pennington KP; Liao JB; Doll KM; Simons EJ; Burzawa JK; Goff BA; Speiser P; Swisher EM; Norquist BM; Risques RA
Cancer Res Commun; 2022 Oct; 2(10):1282-1292. PubMed ID: 36311816
[TBL] [Abstract][Full Text] [Related]
4. Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Wallbillich JJ; Morris RT; Ali-Fehmi R
Gynecol Oncol; 2020 Nov; 159(2):381-386. PubMed ID: 32900500
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Somatic
Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
[TBL] [Abstract][Full Text] [Related]
6. Clonal Evolution of
Garziera M; Cecchin E; Giorda G; Sorio R; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Ecca F; Canzonieri V; Toffoli G
Cells; 2019 Oct; 8(10):. PubMed ID: 31581548
[TBL] [Abstract][Full Text] [Related]
7. Spectrum of
Boyarskikh UA; Gulyaeva LF; Avdalyan AM; Kechin AA; Khrapov EA; Lazareva DG; Kushlinskii NE; Melkonyan A; Arakelyan A; Filipenko ML
Front Oncol; 2020; 10():1103. PubMed ID: 32766142
[No Abstract] [Full Text] [Related]
8. Optimized p53 immunohistochemistry is an accurate predictor of
Köbel M; Piskorz AM; Lee S; Lui S; LePage C; Marass F; Rosenfeld N; Mes Masson AM; Brenton JD
J Pathol Clin Res; 2016 Oct; 2(4):247-258. PubMed ID: 27840695
[No Abstract] [Full Text] [Related]
9. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
[TBL] [Abstract][Full Text] [Related]
10. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations.
Ghezelayagh TS; Pennington KP; Norquist BM; Khasnavis N; Radke MR; Kilgore MR; Garcia RL; Lee M; Katz R; Leslie KK; Risques RA; Swisher EM
Gynecol Oncol; 2021 Mar; 160(3):786-792. PubMed ID: 33375991
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
Liu WL; Wang ZZ; Zhao JZ; Hou YY; Wu XX; Li W; Dong B; Tong TT; Guo YJ
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):26-31. PubMed ID: 28190312
[No Abstract] [Full Text] [Related]
12. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
McAlpine JN; Porter H; Köbel M; Nelson BH; Prentice LM; Kalloger SE; Senz J; Milne K; Ding J; Shah SP; Huntsman DG; Gilks CB
Mod Pathol; 2012 May; 25(5):740-50. PubMed ID: 22282309
[TBL] [Abstract][Full Text] [Related]
13. Germline and tumor
Ji G; Yao Q; Bao L; Zhang J; Bai Q; Zhu X; Tu X; Bi R; Zhou X
Ann Transl Med; 2021 Mar; 9(6):453. PubMed ID: 33850850
[TBL] [Abstract][Full Text] [Related]
14. Profiling extracellular vesicles in circulation enables the early detection of ovarian cancer.
Jo A; Green A; Medina JE; Iyer S; Ohman AW; McCarthy ET; Reinhardt F; Gerton T; Demehin D; Mishra R; Kolin DL; Zheng H; Crum CP; Weinberg RA; Rueda BR; Castro CM; Dinulescu DM; Lee H
bioRxiv; 2023 Jan; ():. PubMed ID: 36711872
[TBL] [Abstract][Full Text] [Related]
15. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
16. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
17.
Wieser V; Gaugg I; Fleischer M; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Zeimet AG; Fiegl H; Marth C
Oncotarget; 2018 Apr; 9(25):17501-17511. PubMed ID: 29707124
[TBL] [Abstract][Full Text] [Related]
18.
Vitale SR; Groenendijk FH; van Marion R; Beaufort CM; Helmijr JC; Dubbink HJ; Dinjens WNM; Ewing-Graham PC; Smolders R; van Doorn HC; Boere IA; Berns EMJJ; Helleman J; Jansen MPHM
Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32156073
[TBL] [Abstract][Full Text] [Related]
19. Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.
He SY; Li YC; Wang Y; Peng HL; Zhou CL; Zhang CM; Chen SL; Yin JF; Lin M
World J Gastroenterol; 2022 Jul; 28(25):2920-2936. PubMed ID: 35978873
[TBL] [Abstract][Full Text] [Related]
20. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
